C4 Therapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.6M | $6.2M | $11.0M | $11.2M | $6.5M | $7.2M | $5.2M | $15.4M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $24.5M | $24.6M | $25.0M | $26.0M | $26.2M | $27.1M | $32.5M | $31.8M |
| SG&A Expense | $8.6M | $9.3M | $9.2M | $8.9M | $8.8M | $9.3M | $10.4M | $11.8M |
| Operating Income | $-26.4M | $-27.8M | $-23.1M | $-34.4M | $-28.5M | $-29.2M | $-37.7M | $-28.2M |
| Operating Margin | -397.9% | -451.6% | -210.1% | -306.4% | -441.0% | -402.9% | -728.4% | -183.9% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | $-20.4M | $-32.2M | $-26.0M | $-26.3M | $-34.4M | $-24.7M |
| Income Tax Expense | $0 | $0 | $121.0K | $0 | $0 | $0 | $131.0K | $0 |
| Net Income | $-23.6M | $-25.1M | $-20.5M | $-32.2M | $-26.0M | $-26.3M | $-34.6M | $-24.7M |
| Net Margin | -355.9% | -408.5% | -186.0% | -286.4% | -402.6% | -363.7% | -667.8% | -160.6% |
| EPS (Basic) | $-0.18 | $-0.20 | $-0.09 | $-0.44 | $-0.37 | $-0.37 | $-0.50 | $-0.35 |
| EPS (Diluted) | $-0.18 | $-0.20 | $-0.09 | $-0.44 | $-0.37 | $-0.37 | $-0.50 | $-0.35 |
| Shares Outstanding (Basic) | 130.7M | 126.1M | 82.9M | 72.6M | 71.0M | 70.8M | 69.4M | 69.6M |
| Shares Outstanding (Diluted) | 130.7M | 126.1M | 82.9M | 72.6M | 71.0M | 70.8M | 69.4M | 69.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |